Instead, targeting PD-1 or CTLA-4 on immune cells might enhance the immune response in both the tumor and also the normal tissues, thereby increasing the risk for more frequent or more severe pulmonary toxicities upon combined use with radiotherapy when compared to a combination of radiotherapy with PD-L1-inhibition. The gene discussed is CD274; the disease is neoplasm.